TOTAL VOLUME:

$154.4b

24H VOL:

$245,801,863

24H TRANSACTIONS:

2,984,028,936

OPEN INTEREST:

$1,902,097,102

417,059

Markets across

40,178

events

MATCHED EVENTS:

4,415

PLATFORM COVERAGE:

5

Polymarket:

37%

VS.

Kalshi:

63%

BETA
Dashboards
Insights
Indices
API
Tour
All
Trending
Breaking
New
Ending Soon
Politics
Sports
Elections
Crypto
Companies
Financials
Economics
Other
Entertainment
Science and Technology
Will Johnson & Johnson (JNJ) Q3 Innovative Medicine revenue be above __?
polymarket

Will JNJ Q3 Innovative Medicine revenue be above?

Volume:
$7,648

$16.6B

 - Polymarket

$16.6B - Polymarket

1W

News

Positive

Negative

Neutral

Hover marker for details

Vol.

·

Resolved Oct 13, 2026

Closed: Oct 13, 8:24 AM EST

polymarket

Polymarket

View
Outcome
Trade
Chance %
Price
Spread
Liquidity
Volume
24h
7d
Open Interest
Ends in
Result
polymarket

$16.6B

View
100%
32%
Yes 100¢No 0¢
—
N/A
$1,004
N/A
N/A
N/A
Settled
Yes
polymarket

$17.2B

View
0%
26%
Yes 0¢No 100¢
—
N/A
$2,296
N/A
N/A
N/A
Settled
No
polymarket

$17.4B

View
0%
5%
Yes 0¢No 100¢
—
N/A
$1,848
N/A
N/A
N/A
Settled
No
polymarket

$17B

View
0%
33%
Yes 0¢No 100¢
—
N/A
$1,367
N/A
N/A
N/A
Settled
No
polymarket

$16.8B

View
0%
21%
Yes 0¢No 100¢
—
N/A
$1,133
N/A
N/A
N/A
Settled
No
Total markets: 5

Description

This market will resolve to "Yes" if Johnson & Johnson's Innovative Medicine revenue for the upcoming third fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Polymarket

This market will resolve to "Yes" if Johnson & Johnson's Innovative Medicine revenue for the upcoming third fiscal quarter, as reported in its official company earnings materials, is above the listed amount. Otherwise, this market will resolve to "No". The specified metric will be considered as reported in the company's official earnings materials. Subsequent revisions will not be considered. If the specified company's official earnings materials for the specified quarter are released, and the specified metric is not included, this market will resolve to "No". If the specified company does not release quarterly earnings materials for the specified quarter by November 30, 2026, 11:59 PM ET, this market will resolve to "No". If the specified metric is reported as a range rather than a specific number, the midpoint of the range will be used for resolution of this market. The resolution source for this market is Johnson & Johnson's official company earnings materials, including press releases, investor presentations, and regulatory filings. If the specified metric is not reported in these materials, recordings or transcripts of the company's earnings webcast may also be used. Note: This market will resolve based on the most numerically precise version of the specified metric reported in the company's official earnings materials. Only the specified metric will be considered; alternate versions that differ in definition or scope from the specified metric will not be considered.

Frequently asked questions

On Polymarket, the dashboard for the JNJ Q3 revenue market displays the current odds, reflecting what traders believe is the probability of Johnson & Johnson’s Q3 Innovative Medicine revenue exceeding a certain threshold. It also provides a price history chart, allowing users to see how the market has fluctuated over time. Finally, the dashboard shows the 24-hour trading volume, currently at $1,508, and the total volume traded to date, which is $7,629. This information helps participants assess market sentiment and potential trading opportunities within this specific market.

Currently, prediction market participants are expressing a view on JNJ’s Q3 revenue that may differ from traditional analyst estimates. While analysts provide point estimates or ranges, this market allows for a probabilistic assessment – traders are essentially putting their money where their mouth is, indicating the likelihood of various outcomes. Comparing the implied probability from this market to the consensus forecast from financial analysts can reveal whether the crowd is more optimistic or pessimistic about JNJ’s performance than experts. It’s a different way of gauging expectations for the company’s financial results.

This market resolves around Oct 13, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. Specifically, the resolution will be based on the official Q3 Innovative Medicine revenue figure reported by Johnson & Johnson in their earnings release. The market will determine whether that reported revenue figure is above the threshold specified in the market question. Traders should monitor JNJ’s investor relations website for the official earnings announcement to understand the final outcome of this market.

Several factors could significantly influence the JNJ Q3 revenue market. Any news regarding clinical trial results for key innovative medicines, regulatory approvals or delays, or broader macroeconomic trends impacting the pharmaceutical industry could shift trader sentiment. Unexpected announcements about major partnerships or acquisitions involving JNJ could also move the market. Furthermore, revisions to analyst estimates for JNJ’s revenue, or any commentary from JNJ management regarding their Q3 performance expectations, would likely be closely watched by traders and impact the price of shares in this market.